New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
NCCN Guidelines Insights: Myelodysplastic Syndromes, Version 3.2022.
NCCN Guidelines Insights: Myelodysplastic Syndromes, Version 3.2022. Journal of the National Comprehensive Cancer Network : JNCCN Greenberg, P. L., Stone, R. M., Al-Kali, A., Bennett, J. M., Borate, U., Brunner, A. M., Chai-Ho, W., Curtin, P., de Castro, C. M., Deeg, H. J., DeZern, A. E., Dinner, S., Foucar, C., Gaensler, K., Garcia-Manero, G., Griffiths, E. A., Head, D., Jonas, B. A., Keel, S., Madanat, Y., Maness, L. J., Mangan, J., McCurdy, S., McMahon, C., Patel, B., Reddy, V. V., Sallman, D. A., Shallis, R., Shami, P. J., Thota, S., Varshavsky-Yanovsky, A. N., Westervelt, P., Hollinger, E., Shead, D. A., Hochstetler, C. 2022; 20 (2): 106-117Abstract
The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and management of patients with MDS based on a review of clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts meets on an annual basis to update the recommendations. These NCCN Guidelines Insights focus on some of the updates for the 2022 version of the NCCN Guidelines, which include treatment recommendations both for lower-risk and higher-risk MDS, emerging therapies, supportive care recommendations, and genetic familial high-risk assessment for hereditary myeloid malignancy predisposition syndromes.
View details for DOI 10.6004/jnccn.2022.0009
View details for PubMedID 35130502